At the ASCO 2025 meeting in Chicago, multiple breakthroughs emerged: pembrolizumab improved head and neck cancer survival; lifileucel helped melanoma patients; CAR‑T increased survival in solid tumors; liquid biopsies became more actionable; exercise was tied to 28% reduced cancer mortality; camizestrant slowed breast tumor growth; and AI tools improved prostate cancer treatment selection. These advancements indicate a move toward precision and personalized cancer care.
Source: The Guardian theguardian.com
0 Comments